Navigation Links
Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China
Date:5/29/2009

DUSSELDORF, Germany, May 29 /PRNewswire-FirstCall/ -- The Gerresheimer Group today opened a new plant for pharmaceutical glass packaging in China. The high-tech production facility constructed in Danyang (Jiangsu Province) covers 16,000 square meters. Specializing in high-quality pharmaceutical vials and cartridges for injection systems it serves the pharma & life science industry on both a local and international level. Dr. Axel Herberg, CEO of Gerresheimer AG, describes the investment as a very important strategic step for further business expansion in Asia. In China, Gerresheimer now operates seven production plants for highly specific glass and plastic products.

The new facility belongs to Gerresheimer Shuangfeng, a Chinese subsidiary of the Group, which was acquired in 2006 and now already has production plants in three locations with a total of more than 150 production lines. With investment in future-oriented technologies and a high-quality range of vials, ampoules and cartridges, it has in just a few years developed into the market leader in China, said Dr. Max Raster, member of the Management Board of Gerresheimer AG with responsibility for the Tubular Glass Division, at the opening ceremony on May 29, 2009.

"'Top quality produced in China' is the corporate philosophy here which binds us directly to the ambitious objectives for development of the local economy and the Jiangsu region," Raster said. At the gala opening he joined Chao Xingsong, the Managing Director of Gerresheimer Danyang, in welcoming representatives from the world of politics and the administration as well as a large number of national and international customers who clearly showed they were impressed by the high technical standard.

The state-of-the-art plant in the up-and-coming city with 800,000 inhabitants just 250 kilometers to the west of Shanghai is of outstanding strategic importance for the globally active Gerresheimer Group. A key area of focus for it is the rapidly growing Asian pharma market with its constantly rising quality demands in terms of packaging and drug delivery. In the unanimous assessment of experts, China is already the fifth largest pharma market in the world.

In parallel with its local status as a technology advanced pharma glass plant the Danyang facility offers ideal conditions and flexible expansion possibilities to enable it to supply customers with high-quality specialist products in neighboring Asian countries and other market regions as well. "We work at the highest level of internationally recognized quality standards," Raster stresses. The technical production processes are for example monitored by in-line camera systems - a product control process which is by no means universal industry practice in China or elsewhere. The clean-room concept also reflects the latest development status.

In Danyang, which has for years been regarded as a highly attractive industrial location for foreign investors in particular, Gerresheimer Shuangfeng also has a second production plant exclusively for pharmaceutical vials. In addition, the company manufactures vials and ampoules in Zhenjiang, also in the Province of Jiangsu. Four other plants of the Gerresheimer Group also manufacture in the country. In total, Gerresheimer employs around 1,500 people in China.

About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in Europe, America and Asia. In the financial year 2008, worldwide sales totalled EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

    Contact Press
    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations
    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com



'/>"/>
SOURCE Gerresheimer AG
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
2. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
3. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
4. Moodys Raises Rating for Gerresheimer
5. Gerresheimer Discontinues Marginal Operations
6. Gerresheimer Further Increases its Sales and Earnings Power
7. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
8. Gerresheimer Substantially Increases Quarterly Operating Profit
9. Following a Record Year in 2008 Gerresheimer Again Sets its Sights on Substantial Growth in 2009
10. 2008 a Record Year for Gerresheimer
11. Cartesian Gridspeed Opens Subsidiary Operation in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), ... surfactant therapies for respiratory diseases, today announced that ... award as a component of employment compensation for ... and Chief Executive Officer.  The award was approved ... 2016 and granted as an inducement material to ...
(Date:2/3/2016)... , Feb. 3, 2016 Ascendis Pharma A/S ... that applies its innovative TransCon technology to address significant ... an upcoming investor conference.Event:2016 Leerink Partners Global Healthcare Conference ... , Wednesday, February 10, 2016 Time:  , 11:55am ... . --> An audio webcast of this ...
(Date:2/3/2016)... N.J. , Feb. 3, 2016 ... totaling more than $1 million for researchers in ... working on health-related research that demonstrates exciting potential. ... round of funding for the New Jersey Health Foundation ... faculty members at these educational institutions— Princeton University, ...
(Date:2/3/2016)... ... 03, 2016 , ... ProMIS Neurosciences is currently in the ... misfolded, propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans ... Following on from the first misfolded Amyloid beta target announced on Nov. 12, ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
Breaking Biology News(10 mins):